Curated News
By: NewsRamp Editorial Staff
November 05, 2026
Scinai Revenue Jumps 167% on CDMO Expansion, Orders Up 330%
TLDR
- Scinai Immunotherapeutics grew revenue 167% to $2.8 million and committed orders surged over 330%, signaling strong competitive momentum.
- Scinai's revenue growth stems from CDMO expansion via the Recipharm Israel acquisition and a $5.1 million U.S. customer agreement.
- Scinai's expanded CDMO services and immunology pipeline aim to advance therapies and manufacturing capacity for better health outcomes.
- Scinai's $6.4 million noncash bargain purchase gain from acquiring Recipharm Israel turned a $6.56 million operating loss into a $390,000 net loss.
Impact - Why it Matters
The sharp revenue growth and surge in committed orders signal that Scinai's CDMO strategy is gaining commercial traction, which could lead to improved financial stability and a longer operational runway. For investors, the company's ability to secure large U.S. customer agreements and extend liquidity into 2028 may reduce near-term financing risks. The acquisition of Recipharm Israel and the bargain purchase gain also highlight management's ability to execute deals that bolster the CDMO business. As Scinai continues to advance its immunology pipeline, the growing CDMO revenue provides a foundation to support therapeutic development, potentially creating value across both segments. This news matters because it demonstrates tangible progress in a biopharma model that blends service revenue with drug development, a combination that can offer more predictable cash flow while pursuing high-risk, high-reward therapies.
Summary
Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company that operates a contract development and manufacturing organization (CDMO) alongside an immunology-focused therapeutic development platform, reported revenue of $2.8 million for the nine months ended Sept. 30, 2026, up 167% from $1.05 million in the prior-year period. The increase reflects expansion of its CDMO operations, including the February acquisition of Recipharm Israel. The company reported an operating loss of $6.56 million and a net loss of $390,000, with the latter benefiting from a $6.4 million noncash bargain purchase gain related to the acquisition.
Scinai also reported approximately $8.32 million in committed customer orders as of Nov. 4, 2026, up more than 330% from year-end 2025, including an expanded U.S. customer agreement with approximately $5.1 million in committed base service fees. The company generated approximately $5.3 million in net proceeds from October financing transactions, bringing reported bank balances to approximately $8.1 million as of Oct. 27. Based on current projections and anticipated customer payments, Scinai expects sufficient operating liquidity through late 2027, with potential additional clinical manufacturing work that could extend its runway into 2028. To view the full press release, visit https://ibn.fm/1OlnB.
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) is focused on the development of innovative immunology therapies and is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI. This release was distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai Revenue Jumps 167% on CDMO Expansion, Orders Up 330%
